CureVac N.V (NASDAQ: CVAC) has a higher price-to-earnings ratio of 6.11x compared to its average ratio, The 36-month beta value for CVAC is at 2.49. Analysts have varying views on the stock, with 2 analysts rating it as a “buy,” 1 rating it as “overweight,” 4 as “hold,” and 0 as “sell.”
The public float for CVAC is 95.51M, and currently, shorts hold a 4.39% of that float. The average trading volume for CVAC on June 20, 2025 was 1.12M shares.
CVAC) stock’s latest price update
CureVac N.V (NASDAQ: CVAC)’s stock price has increased by 0.36 compared to its previous closing price of 5.49. However, the company has seen a -1.61% decrease in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-20 that NEW YORK, June 20, 2025 (GLOBE NEWSWIRE) — Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating CureVac N.V. (NASDAQ: CVAC ) related to its sale to BioNTech SE. Under the terms of the proposed transaction, each CureVac share will be exchanged for approximately $5.46 in BioNTech ADSs. Upon closing of the proposed transaction, CureVac shareholders are expected to own between 4% and 6% of BioNTech. Is it a fair deal?
CVAC’s Market Performance
CVAC’s stock has fallen by -1.61% in the past week, with a monthly rise of 28.74% and a quarterly rise of 85.52%. The volatility ratio for the week is 0.31% while the volatility levels for the last 30 days are 8.24% for CureVac N.V The simple moving average for the last 20 days is 16.26% for CVAC stock, with a simple moving average of 64.86% for the last 200 days.
Analysts’ Opinion of CVAC
Many brokerage firms have already submitted their reports for CVAC stocks, with Jefferies repeating the rating for CVAC by listing it as a “Hold.” The predicted price for CVAC in the upcoming period, according to Jefferies is $5 based on the research report published on June 13, 2025 of the current year 2025.
Leerink Partners, on the other hand, stated in their research note that they expect to see CVAC reach a price target of $4, previously predicting the price at $12. The rating they have provided for CVAC stocks is “Market Perform” according to the report published on April 25th, 2024.
SVB Securities gave a rating of “Outperform” to CVAC, setting the target price at $13 in the report published on June 08th of the previous year.
CVAC Trading at 39.74% from the 50-Day Moving Average
After a stumble in the market that brought CVAC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -3.67% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CVAC starting from Thaminda Ramanayake, who proposed sale 6,986 shares at the price of $3.34 back on May 07 ’25. After this action, Thaminda Ramanayake now owns shares of CureVac N.V, valued at $23,316 using the latest closing price.
Myriam Mendila, the affiliate of CureVac N.V, proposed sale 17,839 shares at $4.93 during a trade that took place back on Jan 07 ’25, which means that Myriam Mendila is holding shares at $88,019 based on the most recent closing price.
Stock Fundamentals for CVAC
Current profitability levels for the company are sitting at:
- 0.33 for the present operating margin
- 0.8 for the gross margin
The net margin for CureVac N.V stands at 0.3. The total capital return value is set at 0.24. Equity return is now at value 34.46, with 26.30 for asset returns.
Based on CureVac N.V (CVAC), the company’s capital structure generated 0.05 points at debt to capital in total, while cash flow to debt ratio is standing at 2.61.
Currently, EBITDA for the company is 209.69 million with net debt to EBITDA at -2.19. When we switch over and look at the enterprise to sales, we see a ratio of 1.19. The receivables turnover for the company is 16.27for trailing twelve months and the total asset turnover is 0.67. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.65.
Conclusion
In conclusion, CureVac N.V (CVAC) has had a better performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
